COO or MMSI: Which Is the Better Value Stock Right Now?

Zacks compares The Cooper Companies (COO) and Merit Medical (MMSI) for value investors and finds COO the stronger pick—COO carries a Zacks Rank #2 (Buy) versus MMSI’s #3 (Hold) and has seen more favorable earnings estimate revisions. Valuation metrics tilt to COO as well: forward P/E 17.56 vs. MMSI 22.36, PEG 2.26 vs. 2.32, and P/B 1.89 vs. 3.23, yielding a Value grade of B for COO and C for MMSI. On this basis Zacks concludes COO is the more attractive value opportunity in the medical-dental supplies sector right now.

Analysis

Zacks' comparison positions The Cooper Companies (COO) as the more attractive value candidate versus Merit Medical (MMSI) based on earnings-estimate revision trends and Zacks Ranks: COO carries a Zacks Rank #2 (Buy) while MMSI is a #3 (Hold), and the article explicitly states COO has likely seen a stronger improvement to its earnings outlook. Valuation metrics favor COO with a forward P/E of 17.56 versus MMSI's 22.36, a PEG of 2.26 versus 2.32, and a P/B of 1.89 versus 3.23, producing a Value grade of B for COO and C for MMSI. Market sentiment captured in the piece and signals is mildly positive overall (sentiment score 0.28) with per-ticker sentiment tilted toward COO (0.5) and negative for MMSI (-0.3), reinforcing the short-term market preference for COO. The report also highlights limitations for value buyers: both PEG ratios exceed 2 and the article does not provide detailed revenue, margin or cash-flow figures, so the apparent valuation edge for COO rests primarily on estimate revisions and relative multiples rather than clear evidence of deep undervaluation.

Key Decisions for Investors

• Tilt value exposure toward COO over MMSI given COO's Zacks Rank #2, stronger estimate revisions, and more attractive multiples (forward P/E 17.56, P/B 1.89),
• Monitor earnings-estimate revisions and any change in Zacks Rank for both names and consider trimming or avoiding new exposure to MMSI until revision momentum improves,
• Size positions prudently because PEGs for both stocks are above 2 (COO 2.26, MMSI 2.32), indicating growth expectations are already priced in and neither appears deeply cheap,
• Require upcoming fundamental data (quarterly revenue, margins, cash flow) to validate the valuation gap before meaningfully increasing exposure; use revision activity and sentiment shifts as interim catalysts